HomeCompareGNTLF vs PLD

GNTLF vs PLD: Dividend Comparison 2026

GNTLF yields 200.00% · PLD yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GNTLF wins by $112.86M in total portfolio value
10 years
GNTLF
GNTLF
● Live price
200.00%
Share price
$1.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$119.36M
Annual income
$60,176,096.29
Full GNTLF calculator →
PLD
PLD
● Live price
3.18%
Share price
$128.78
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.50M
Annual income
$5,256,436.18
Full PLD calculator →

Portfolio growth — GNTLF vs PLD

📍 GNTLF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGNTLFPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GNTLF + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GNTLF pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GNTLF
Annual income on $10K today (after 15% tax)
$17,000.00/yr
After 10yr DRIP, annual income (after tax)
$51,149,681.85/yr
PLD
Annual income on $10K today (after 15% tax)
$270.62/yr
After 10yr DRIP, annual income (after tax)
$4,467,970.75/yr
At 15% tax rate, GNTLF beats the other by $46,681,711.09/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GNTLF + PLD for your $10,000?

GNTLF: 50%PLD: 50%
100% PLD50/50100% GNTLF
Portfolio after 10yr
$62.93M
Annual income
$32,716,266.23/yr
Blended yield
51.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

GNTLF
Analyst Ratings
1
Sell
Consensus: Sell
Altman Z
135.3
Piotroski
3/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+5.6% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GNTLF buys
0
PLD buys
0
No recent congressional trades found for GNTLF or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGNTLFPLD
Forward yield200.00%3.18%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$119.36M$6.50M
Annual income after 10y$60,176,096.29$5,256,436.18
Total dividends collected$112.49M$6.37M
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusSellBuy

Year-by-year: GNTLF vs PLD ($10,000, DRIP)

YearGNTLF PortfolioGNTLF Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$30,700$20,000.00$11,255$555.24+$19.4KGNTLF
2$90,232$57,383.18$13,062$1,018.59+$77.2KGNTLF
3$254,173$157,624.56$15,903$1,926.67+$238.3KGNTLF
4$686,927$414,961.74$20,839$3,823.32+$666.1KGNTLF
5$1,783,118$1,048,106.39$30,464$8,166.08+$1.75MGNTLF
6$4,450,613$2,542,677.12$52,054$19,457.30+$4.40MGNTLF
7$10,693,420$5,931,263.38$109,886$54,188.93+$10.58MGNTLF
8$24,760,608$13,318,648.86$304,030$186,451.18+$24.46MGNTLF
9$55,315,649$28,821,798.66$1,166,125$840,813.32+$54.15MGNTLF
10$119,363,841$60,176,096.29$6,504,190$5,256,436.18+$112.86MGNTLF

GNTLF vs PLD: Complete Analysis 2026

GNTLFStock

Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include cardiovascular, type 2 diabetes, prostate cancer, and melanoma. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.

Full GNTLF Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this GNTLF vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GNTLF vs SCHDGNTLF vs JEPIGNTLF vs OGNTLF vs KOGNTLF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.